Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24774474 | 0.84 | SIGMAR1 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL24774489 | 0.83 | TMEM97 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL24774477 | 0.83 | OPRM1 (0.42) | OPRM1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL24775976 | 0.80 | CHRNA7 (0.39) | OPRM1OPRK1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL24775973 | 0.80 | CHRNA7 (0.39) | OPRM1OPRK1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL24775160 | 0.80 | CHRNA7 (0.39) | OPRM1OPRK1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL24775427 | 0.78 | RIPK1 (0.33) | — | |
| SCHEMBL24775980 | 0.76 | CHRNA7 (0.38) | OPRM1OPRK1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL24775978 | 0.76 | CHRNA7 (0.38) | OPRM1OPRK1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL24775422 | 0.76 | OPRM1 (0.40) | OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | OPRM1 4833/4885OPRD1 4591/4885OPRK1 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.